Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BA5K
|
||||
| Former ID |
DIB011008
|
||||
| Drug Name |
Apaxifylline
|
||||
| Synonyms |
BIIP-20; U-98950; BIIP-20-XX
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Phase 2 | [1] | ||
| Company |
Boehringer Ingelheim Corp
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H22N4O3
|
||||
| Canonical SMILES |
c12c(n(c(=O)n(c1=O)CCC)CCC)[nH]c(n2)C1CC(=O)CC1
|
||||
| CAS Number |
CAS 151581-23-6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Xanthines as Adenosine Receptor Antagonists. Handb Exp Pharmacol. 2011; (200): 10.1007/978-3-642-13443-2_6. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.